Nivalis Therapeutics (NVLS) Doses First Patient in N91115 Phase 2 as CF Treatment
Tweet Send to a Friend
Nivalis Therapeutics (Nasdaq: NVLS) announced the first patient was dosed in the Phase 2 clinical study of its lead investigational ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
